Week In Review: Alphamab Raises $234 Million In Hong Kong IPO; Climbs 35% In First Trading Session [Seeking Alpha]
BeiGene, Ltd. - American Depositary Shares (BGNE)
Last beigene, ltd. - american depositary shares earnings: 3/2 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.beigene.com/phoenix.zhtml?c=254246&p=irol-irhome_pf
Company Research
Source: Seeking Alpha
Summary Alphamab Oncology raised $234 million in a Hong Kong IPO and traded 35% higher from its offering price to a market cap of $1.2 billion. AstraZeneca was authorized to market Imfinzi (durvalumab), its PD-L1 immunotherapy, in China as a treatment for patients with unresectable, Stage III non-small cell lung cancer. BeiGene of Beijing released positive clinical results from three trials of its BTK inhibitor Brukinsa at this year's American Society of Hematology Meeting. Deals and Financings Alphamab Oncology (HK: 9966) - KN046 (PD-L1/CTLA4) and KN026 (HER2) - in Phase II tests. It has eight biologics in development. About half of the proceeds will be used to support clinical development of KN046 for various solid tumors. Alphamab Oncology was spun out from Alphamab last year. JOINN Biologics, a US-China biologics CDMO, 3SBio (HK:1530) of Shenyang invested $15.2 million in Zurich's Numab Therapeutics B round and will, in return, have rights to develop up to five novel Numab multi-s
Show less
Read more
Impact Snapshot
Event Time:
BGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BGNE alerts
High impacting BeiGene, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BGNE
News
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual MeetingBusiness Wire
- BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $235.00 to $236.00. They now have a "buy" rating on the stock.MarketBeat
- With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners [Yahoo! Finance]Yahoo! Finance
- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
BGNE
Earnings
- 2/26/24 - Beat
BGNE
Sec Filings
- 4/23/24 - Form 8-K
- 4/15/24 - Form PRE
- 4/11/24 - Form 4
- BGNE's page on the SEC website